This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
National Health Service
see PharmacoEconomics & Outcomes News 838 p36; 803425772
NICE. Appeal panel rules that NICE needs to request evidence for erenumab effectiveness in subgroup of people with chronic migraine. Internet Document : 4 Feb 2020. Available from: URL: https://www.nice.org.uk/news/article/appeal-panel-rules-that-nice-needs-to-request-evidence-for-erenumab-effectiveness-in-subgroup-of-people-with-chronic-migraine
About this article
Cite this article
NICE requires further evidence on erenumab. PharmacoEcon Outcomes News 846, 37 (2020). https://doi.org/10.1007/s40274-020-6576-0